Paper Details

  1. Home
  2. Paper Details

Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder.

Author: ChenChangzheng, GommollCarl, KramerKenneth, SambunarisAngelo, ThaseMichael E

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Levomilnacipran extended-release (ER) has been shown to improve motivation/energy in patients with major depressive disorder (MDD). This study found that improvements in functional impairment were considerably mediated by improvements in motivation/energy, particularly in patients with lower motivation/energy at baseline.
Paper Details　
Original Abstract of the Article :
The objective of this post-hoc analysis was to investigate the relationship between motivation/energy and functional impairment in patients with major depressive disorder (MDD). Data were taken from a phase 3 trial of levomilnacipran extended-release (ER) in adults with MDD (NCT01034462; N=429) that...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049949/

データ提供：米国国立医学図書館（NLM）

Effects of Levomilnacipran Extended-Release on Motivation/Energy and Functioning in Adults with Major Depressive Disorder

This study, like a desert explorer seeking to understand the complexities of the human mind, investigates the effects of levomilnacipran extended-release (ER) on motivation, energy, and functional impairment in adults with major depressive disorder (MDD). The researchers, armed with clinical data from a phase 3 trial, conducted a post-hoc analysis to explore the relationship between these factors. Their findings offer valuable insights into the therapeutic potential of levomilnacipran ER for individuals with MDD.

Levomilnacipran ER: A Potential Oasis for Motivation and Functioning

The study found that levomilnacipran ER was associated with significant improvements in motivation, energy, and functional impairment in adults with MDD, particularly those with lower motivation and energy at baseline. These findings, like a refreshing oasis in the desert of depression, offer hope for individuals struggling with this debilitating condition. The research highlights the importance of addressing the multifaceted symptoms of MDD, including motivational and functional deficits.

Navigating the Desert of Depression: A Journey to Well-being

This study, like a map guiding a traveler through a vast and often challenging desert, sheds light on the potential of levomilnacipran ER for improving motivation, energy, and functional impairment in individuals with MDD. The findings encourage further research into the therapeutic mechanisms of this medication and highlight the importance of a holistic approach to treating depression, addressing both emotional and functional aspects of the condition.

Dr. Camel's Conclusion

This study, like a wise camel navigating a treacherous desert, provides valuable insights into the therapeutic potential of levomilnacipran ER for individuals with MDD. The findings highlight the importance of addressing the multifaceted symptoms of depression, including motivational and functional deficits. This research encourages further exploration of innovative therapies that aim to improve the quality of life for individuals struggling with this challenging condition.
Date :
  1. Date Completed 2017-11-27
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27455513

DOI: Digital Object Identifier

PMC5049949

Related Literature

Article Analysis
・Effects of levomilnacipran
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.